- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04160975
Persuasion in Medicine: Experimental Evidence on Sender and Signal Effects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Cambridge, Massachusetts, United States, 02138
- Harvard University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age: See above.
- Education: Less than a college degree.
- Gender: Male.
- Race: Caucasian or African American.
- Miscellaneous: Has not received the flu shot in the current flu season yet.
- Miscellaneous: Has sound on his device turned on.
Exclusion Criteria:
- Fast survey-taking: subjects who are among the 5% fastest in terms of total time spent on survey within race and treatment group.
- Nonsense answers (those that do not have decipherable English) in the open text sections that suggest low effort.
- Inconsistent responses to questions (such as being willing to give up $10 to receive a flu coupon but not $1).
- Repeat survey takers as indicated by duplicate emails or IP addresses in survey data.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Black R/Race C/Doctor/Standard Script
Video which contains a racially concordant actor playing a doctor and reading a standard script.
The receiver of the message will be Black.
|
The investigators will show subjects videos of either Black or white male actors providing scripted information on the flu vaccination.
The content of the video will be the safety and effectiveness of adult seasonal flu vaccination.
The videos contain one of Black or white actors playing the role of either a doctor or a layperson as well as different scripts.
|
Experimental: Black R/Race C/Layperson/Standard Script
Video which contains a racially concordant actor playing a layperson and reading a standard script.
The receiver of the message will be Black.
|
The investigators will show subjects videos of either Black or white male actors providing scripted information on the flu vaccination.
The content of the video will be the safety and effectiveness of adult seasonal flu vaccination.
The videos contain one of Black or white actors playing the role of either a doctor or a layperson as well as different scripts.
|
Experimental: Black R/Race D/Doctor/Standard Script
Video which contains a racially discordant actor playing a doctor and reading a standard script.
The receiver of the message will be Black.
|
The investigators will show subjects videos of either Black or white male actors providing scripted information on the flu vaccination.
The content of the video will be the safety and effectiveness of adult seasonal flu vaccination.
The videos contain one of Black or white actors playing the role of either a doctor or a layperson as well as different scripts.
|
Experimental: Black R/Race D/Doctor/Acknowledgement Script
Video which contains a racially discordant actor playing a doctor and reading an acknowledgement script.
The receiver of the message will be Black.
|
The investigators will show subjects videos of either Black or white male actors providing scripted information on the flu vaccination.
The content of the video will be the safety and effectiveness of adult seasonal flu vaccination.
The videos contain one of Black or white actors playing the role of either a doctor or a layperson as well as different scripts.
|
Experimental: White R/Race C/Doctor/Standard Script
Video which contains a racially concordant actor playing a doctor and reading a standard script.
The receiver of the message will be White.
|
The investigators will show subjects videos of either Black or white male actors providing scripted information on the flu vaccination.
The content of the video will be the safety and effectiveness of adult seasonal flu vaccination.
The videos contain one of Black or white actors playing the role of either a doctor or a layperson as well as different scripts.
|
Experimental: White R/Race D/Doctor/Standard Script
Video which contains a racially discordant actor playing a doctor and reading a standard script.
The receiver of the message will be White.
|
The investigators will show subjects videos of either Black or white male actors providing scripted information on the flu vaccination.
The content of the video will be the safety and effectiveness of adult seasonal flu vaccination.
The videos contain one of Black or white actors playing the role of either a doctor or a layperson as well as different scripts.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rating of Sender
Time Frame: This outcome was assessed during Baseline survey, which took approximately 20 minutes.
|
This is an inverse-covariance-weighted index comprised of responses to survey questions regarding:
It is standardized to a mean of 0 and standard deviation of 1. Scores less than 0 indicate lower ratings of the sender rated by participants in Arm A (described in each arm/group description) compared to the rating rated by participants in Arm B (also described in each arm/group description). Scores greater than 0 indicate higher ratings of the sender by Arm A compared to by Arm B. For example, an index score of .18 indicates that participants in Arm A rate the sender 0.18 index (in standard deviation units) higher than those in Arm B. |
This outcome was assessed during Baseline survey, which took approximately 20 minutes.
|
Rating of Signal
Time Frame: This outcome was assessed during Baseline survey, which took approximately 20 minutes.
|
This is an inverse-covariance-weighted index comprised of responses to survey questions on:
It is standardized to a mean of 0 and standard deviation of 1. An index score of 0 is equal to the mean. Scores less than 0 indicate lower ratings of the signal rated by participants in Arm A (described in each arm/group description) compared to the rating rated by participants in Arm B (also described in each arm/group description). Scores greater than 0 indicate higher ratings of the signal by Arm A compared to by Arm B. For example, an index score of 0.14 indicates that participants in Arm A rate the signal 0.14 index (in standard deviation units) higher than those in Arm B. |
This outcome was assessed during Baseline survey, which took approximately 20 minutes.
|
Signal Content Recall
Time Frame: This outcome will be assessed during Baseline survey, which takes approximately 20 minutes.
|
This is an inverse-covariance-weighted index comprised of responses to survey questions on:
It is standardized to a mean of 0 and standard deviation of 1. An index score of 0 is equal to the mean. Scores less than 0 indicate lower level of recalling signal content among participants in Arm A (described in each arm/group description) compared to the level among participants in Arm B (also described in each arm/group description). Scores greater than 0 indicate a higher level of recalling signal content among participants in Arm A compared to those in Arm B. For example, an index score of 0.02 indicates that participants in Arm A recall signal content 0.02 index (in standard deviation units) higher than those in Arm B. |
This outcome will be assessed during Baseline survey, which takes approximately 20 minutes.
|
Safety Beliefs
Time Frame: This outcome will be assessed during Baseline survey, which takes approximately 20 minutes.
|
This is an inverse-covariance-weighted index comprised of:
It is standardized to a mean of 0 and standard deviation of 1. An index score of 0 is equal to the mean. Scores less than 0 indicate a lower level of beliefs in the safety of flu vaccine among participants in Arm A (described in each arm/group description) compared to the level among participants in Arm B (also described in each arm/group description). Scores greater than 0 indicate a higher level of beliefs among participants in Arm A compared to those in Arm B. For example, an index score of -0.1 indicates that participants in Arm A hold such beliefs 0.1 index (in standard deviation units) lower than those in Arm B. |
This outcome will be assessed during Baseline survey, which takes approximately 20 minutes.
|
Coupon Interest
Time Frame: This outcome was assessed during Baseline survey, which took approximately 20 minutes.
|
This is an inverse-covariance-weighted index comprised of revealed preference measures of demand for a free flu shot coupon:
It is standardized to a mean of 0 and standard deviation of 1. An index score of 0 is equal to the mean. Scores less than 0 indicate a lower level of interest in a free flu shot coupon distributed after survey completion among participants in Arm A (described in each arm/group description) compared to the level among participants in Arm B (also described in each arm/group description). Scores greater than 0 indicate a higher level of interest among participants in Arm A compared to those in Arm B. For example, an index score of -0.01 indicates that participants in Arm A hold such interest -0.01 index (in standard deviation units) higher than those in Arm B. |
This outcome was assessed during Baseline survey, which took approximately 20 minutes.
|
(Posterior) Flu Vaccine Intent
Time Frame: This outcome was assessed after the video treatment during Baseline survey, which took approximately 20 minutes.
|
This is the respondent's likelihood to receive the flu vaccine before the end of the flu season.
This was elicited on an 11-point Likert scale (0 extremely unwilling, 10 extremely willing) after the video message treatment.
We re-scaled this outcome to have a scale of 0 to 1.
The reported results of the outcome compare participants in Arm A and Arm B (described in each arm/group description).
For example, an intent of 0.03 indicates that participants in Arm A are 0.03 units on a scale more likely to intent to take up the flu vaccine compared to those in Arm B.
|
This outcome was assessed after the video treatment during Baseline survey, which took approximately 20 minutes.
|
COVID-19 Vaccine Intent
Time Frame: This outcome was assessed after the video treatment during Baseline survey, which took approximately 20 minutes.
|
This is the respondent's likelihood to take up the COVID-19 vaccine if made available free of charge.
This was elicited on an 11-point Likert scale (0 extremely unwilling, 10 extremely willing) after the video message treatment.
We re-scaled this outcome to have a scale of 0 to 1.
The reported results of the outcome compare participants in Arm A and Arm B (described in each arm/group description).
For example, an intent of 0.04 indicates that participants in Arm A are 0.04 units on a scale more likely to intent to take up the COVID-19 vaccine compared to those in Arm B.
|
This outcome was assessed after the video treatment during Baseline survey, which took approximately 20 minutes.
|
Flu Vaccine Take-up
Time Frame: This outcome was assessed during the follow-up survey which was conducted at least two weeks after the initial baseline survey.
|
This is respondents' self-report in the follow-up survey on whether they or their family members had received the flu shot or redeemed the coupon since the intervention.
The reported results of the outcome compare participants in Arm A and Arm B (described in each arm/group description).
For example, 15.0 percentage points indicate that participants in Arm A are more likely to report that they and/or another household member received the flu vaccine by 15.p percentage points compared to those in Arm B.
|
This outcome was assessed during the follow-up survey which was conducted at least two weeks after the initial baseline survey.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB19-1424
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
Clinical Trials on Video about safety and effectiveness of adult seasonal flu vaccination
-
Liquidia Technologies, Inc.Children's Hospital Medical Center, Cincinnati; AccelovanceCompleted